Boston Scientific, Watchman FLX
Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...
Zacks.com on MSN14h
Boston Scientific Stock Set to Gain From Completion of Axonics DealBoston Scientific Corporation BSX recently closed the acquisition of Axonics, Inc., a medical technology company focused on the development and commercialization of differentiated devices to treat ...
GlobalData on MSN1d
Boston Scientific reports outcomes from trial of LAAC deviceThe trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.
15h
Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...
AVVIGO is an intravascular ultrasound (IVUS) and fractional flow reserve (FFR) system designed to provide high-quality IVUS ...
Boston Scientific Corp. last week announced that it has closed on its acquisition of Irvine-based medical device maker ...
for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at ...
Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...
Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).
In a report released today, Richard Newitter from Truist Financial assigned a Buy rating to Boston Scientific (BSX – Research Report). The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback